4-氯-6-甲氧基-2-甲基喹唑啉 | 60395-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-氯-6-甲氧基-2-甲基喹唑啉
• 英文名称: 4-Chloro-6-methoxy-2-methylquinazoline
• CAS: 60395-90-6
• 化学式: C₁₀H₉ClN₂O
• mdl: MFCD12024901
• 分子量: 208.64
• InChiKey: YOQQPWWCYHJCGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氯-6-甲氧基-2-甲基喹唑啉 以83%的产率得到
  参考文献：
  名称：

  ZHIXAREVA G. P.; PRONINA E. V.; GOLOVANOVA E. A.; PERSHIN G. N.; NOVITSKA+, XIM.-FARMATSEVT. ZH. , 1976, 10, HO 4, 62-66

  摘要：

  DOI：
• 作为产物：
  描述：

  6-methoxy-2-methylquinazolin-4-ol 、 三氯氧磷 以88%的产率得到
  参考文献：
  名称：

  ZHIXAREVA G. P.; PRONINA E. V.; GOLOVANOVA E. A.; PERSHIN G. N.; NOVITSKA+, XIM.-FARMATSEVT. ZH. , 1976, 10, HO 4, 62-66

  摘要：

  DOI：

文献信息

• Compounds useful as chemokine receptor antagonists
  申请人：Carson G. Kenneth

  公开号：US20060172994A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.

  本发明涉及作为趋化因子受体拮抗剂有用的化合物。提供了一般式I的化合物：或其药学上可接受的盐。本发明还提供了包含所述化合物的药学上可接受的组合物以及使用所述化合物和组合物抑制趋化因子受体以及治疗各种疾病、病症或紊乱的方法，包括急性或慢性炎症性疾病、癌症或骨溶解性骨病。
• Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US07880002B2

  公开（公告）日：2011-02-01

  The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.

  本发明涉及用作趋化因子受体拮抗剂的化合物。提供一般式I的化合物：或其药学上可接受的盐。本发明还提供了包含该化合物的药学上可接受的组合物以及使用该化合物和组合物来抑制趋化因子受体以及治疗各种疾病、状况或障碍的方法，包括急性或慢性炎症性疾病、癌症或骨质疏松性骨疾病。
• SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS
  申请人：Carson Kenneth G.

  公开号：US20130123270A1

  公开（公告）日：2013-05-16

  The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.

  本发明涉及化合物，作为趋化因子受体拮抗剂有用。提供了一般式I的化合物：或其药学上可接受的盐。该发明还提供了包括所述化合物的药学上可接受的组合物，并使用该化合物和组合物来抑制趋化因子受体以及治疗各种疾病，病况或障碍，包括急性或慢性炎症性疾病，癌症或骨溶解性骨疾病的方法。
• NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20210177851A1

  公开（公告）日：2021-06-17

  The present invention encompasses compounds of formula (I) wherein the groups R 1 to R 7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
• US7880002B2
  申请人：——

  公开号：US7880002B2

  公开（公告）日：2011-02-01